Literature DB >> 20810900

Parkin directly modulates 26S proteasome activity.

Ji Won Um1, Eunju Im, Hyun Jung Lee, Boram Min, Lang Yoo, Jiho Yoo, Hermann Lübbert, Christine Stichel-Gunkel, Hyun-Soo Cho, Jong Bok Yoon, Kwang Chul Chung.   

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease that involves the deterioration of dopaminergic neurons in the substantia nigra pars compacta. Although the etiology of PD remains poorly understood, recent genetic, postmortem, and experimental evidence shows that abnormal protein accumulation and subsequent aggregate formation are prominent features of both sporadic and familial PD. While proteasome dysfunction is observed in PD, diverse mutations in the parkin gene are linked to early-onset autosomal-recessive forms of familial PD. We demonstrate that parkin, an E3 ubiquitin ligase, activates the 26S proteasome in an E3 ligase activity-independent manner. Furthermore, an N-terminal ubiquitin-like domain within parkin is critical for the activation of the 26S proteasome through enhancing the interaction between 19S proteasomal subunits, whereas the PD-linked R42P mutant abolishes this action. The current findings point to a novel role for parkin for 26S proteasome assembly and suggest that parkin mutations contribute to the proteasomal dysfunction in PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810900      PMCID: PMC6633428          DOI: 10.1523/JNEUROSCI.2862-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  26 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

2.  Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes.

Authors:  Gustavo Martínez-Noël; Jeffrey T Galligan; Mathew E Sowa; Verena Arndt; Thomas M Overton; J Wade Harper; Peter M Howley
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

3.  Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.

Authors:  Sher Hayat Khan; Deming Zhao; Syed Zahid Ali Shah; Mohammad Farooque Hassan; Ting Zhu; Zhiqi Song; Xiangmei Zhou; Lifeng Yang
Journal:  Cell Mol Neurobiol       Date:  2016-07-18       Impact factor: 5.046

Review 4.  Regulation of proteasome activity in health and disease.

Authors:  Marion Schmidt; Daniel Finley
Journal:  Biochim Biophys Acta       Date:  2013-08-27

5.  Policing Parkin with a UblD.

Authors:  Fen Liu; Kylie J Walters
Journal:  EMBO J       Date:  2011-07-20       Impact factor: 11.598

6.  The requirement for Cdc48/p97 in nuclear protein quality control degradation depends on the substrate and correlates with substrate insolubility.

Authors:  Pamela S Gallagher; Sarah V Clowes Candadai; Richard G Gardner
Journal:  J Cell Sci       Date:  2014-02-25       Impact factor: 5.285

7.  The E3 ubiquitin ligase parkin is recruited to the 26 S proteasome via the proteasomal ubiquitin receptor Rpn13.

Authors:  Miguel A Aguileta; Jelena Korac; Thomas M Durcan; Jean-François Trempe; Michael Haber; Kalle Gehring; Suzanne Elsasser; Oliver Waidmann; Edward A Fon; Koraljka Husnjak
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

8.  NADH binds and stabilizes the 26S proteasomes independent of ATP.

Authors:  Peter Tsvetkov; Nadav Myers; Raz Eliav; Yaarit Adamovich; Tzachi Hagai; Julia Adler; Ami Navon; Yosef Shaul
Journal:  J Biol Chem       Date:  2014-03-04       Impact factor: 5.157

Review 9.  The biology of proteostasis in aging and disease.

Authors:  Johnathan Labbadia; Richard I Morimoto
Journal:  Annu Rev Biochem       Date:  2015-03-12       Impact factor: 23.643

10.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.